BREAKTHROUGH Medicine FDA approved 9/11/23
Aphexdra (motixafortide) has been approved by the FDA and is the FIRST
innovation in ten years for multiple myeloma patients. This novel medicine
is to be used in combination with Filgrastim (G-CSF) to mobilize crucial
Stem Cells for collection and Subsequent patient transplant (Autologous) in
people with Multiple Myeloma.
Multiple myeloma (MM) is a cancer of the blood that does NOT have a cure.
This incurable cancer affects a crucial kind of white blood cell called a
plasma cell in the bone marrow. In MM patients, these abnormal plasma cells
spread and replace normal cells and this diagnosis happens in more than
35,000 in the US. Nearly 13,000 patients die from MM each year (Click here to read more).